SciClone report positive hep C data

SciClone Pharmaceuticals and Sigma-Tau are reporting positive interim data from a Phase III trial of Zadaxin for hepatitis C. At the end of 48 weeks, the blinded data show that 171 out of 553 total patients, including both treatment and control group patients, responded to treatment. "These interim HCV data are promising because, although we do not know the breakdown between thymalfasin treated and control group patients who have achieved an SVR, this is already a strong overall response for nonresponder patients," said Mario Rizzetto, M.D., lead investigator of the trial. Full results of the trial will be available in the third quarter.

- see this release for more

Suggested Articles

Xevinapant in combination with standard cisplatin-based chemoradiation therapy (CRT) reduces the risk of death in high-risk patients with locally adva

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.

Junshi’s PD-1 blocker is already approved in China for metastatic melanoma, but the Shanghai-based biotech may soon add throat cancer to its label.